BDR Pharmaceuticals has launched enzalutamide in 160 mg strength for the convenience of prostrate cancer patients. It markets it under the brand name Bdenza.

This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage. It is primarily used to treat prostrate cancer patients.

The objective behind the launch of enzalutamide 160mg is to ensure better efficacy, minimum side effects, contain relapse cases by blocking the hormones of cancer cells providing an evolved treatment.

Raheel Shah, Director Business Development, BDR Pharmaceuticals Int’l said, “Our focused launch of such expanded brand strength will definitely add value to our oncology patients as well as provide an opportunity to doctors to comply with patient outcome and standard treatment protocol. This represents a firm commitment to providing access to affordable medicines for Indian cancer patients with high a quality standard”.

“As a key player in the manufacture of cancer medicines, BDR Pharmaceuticals propagates affordability and is recognised as a niche entity in manufacturing of pharmaceutical APIs and for the renowned new age formulations.”, added Shah.